Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Opinion Article

Evaluating Lean Liver Volume as a Potential Scaler for In Vitro-In Vivo Extrapolation of Drug Clearance in Obesity Using the Model Drug Antipyrine

Author(s): Jaydeep Sinha*, Stephen B. Duffull, Bruce Green and Hesham S. Al-Sallami

Volume 21, Issue 10, 2020

Page: [746 - 750] Pages: 5

DOI: 10.2174/1389200221666200515105800

Price: $65

Abstract

Background: In vitro-in vivo extrapolation (IVIVE) of hepatic drug clearance (CL) involves the scaling of hepatic intrinsic clearance (CLint,uH) by functional liver size, which is approximated by total liver volume (LV) as per the convention. However, in most overweight and obese patients, LV includes abnormal liver fat, which is not thought to contribute to drug elimination, thus overestimating drug CL. Therefore, lean liver volume (LLV) might be a more appropriate scaler of CLint,uH.

Objective: The objective of this work was to assess the application of LLV in CL extrapolation in overweight and obese patients (BMI >25 kg/m2) using a model drug antipyrine.

Methods: Recently, a model to predict LLV from patient sex, weight, and height was developed and evaluated. In order to assess the LLV model’s use in IVIVE, a correlation-based analysis was conducted using antipyrine as an example drug.

Results: In the overweight group (BMI >25 kg/m2), LLV could describe 36% of the variation in antipyrine CL (R2 = 0.36), which was >2-fold higher than that was explained by LV (R2 = 0.17). In the normal-weight group (BMI ≤25 kg/m2), the coefficients of determination were 58% (R2 = 0.58) and 43% (R2= 0.43) for LLV and LV, respectively.

Conclusion: The analysis indicates that LLV is potentially a more appropriate descriptor of functional liver size than LV, particularly in overweight individuals. Therefore, LLV has a potential application in IVIVE of CL in obesity.

Keywords: IVIVE, NAFLD, NASH, PBPK, FFM, drug development, obesity, lean liver volume, functional liver volume.

« Previous Next »
Graphical Abstract

[1]
Blouin, R.A.; Warren, G.W. Pharmacokinetic considerations in obesity. J. Pharm. Sci., 1999, 88(1), 1-7.
[http://dx.doi.org/10.1021/js980173a ] [PMID: 9874695]
[2]
Cheymol, G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin. Pharmacokinet., 2000, 39(3), 215-231.
[http://dx.doi.org/10.2165/00003088-200039030-00004 ] [PMID: 11020136]
[3]
Hanley, M.J.; Abernethy, D.R.; Greenblatt, D.J. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet., 2010, 49(2), 71-87.
[http://dx.doi.org/10.2165/11318100-000000000-00000 ] [PMID: 20067334]
[4]
Leykin, Y.; Miotto, L.; Pellis, T. Pharmacokinetic considerations in the obese. Best Pract. Res. Clin. Anaesthesiol., 2011, 25(1), 27-36.
[http://dx.doi.org/10.1016/j.bpa.2010.12.002 ] [PMID: 21516911]
[5]
Princeton, NJ Covance Inc. NASH: Key considerations for drug development, Available from: https://www.covance.com/content/dam/covance/assetLibrary/whitepapers/NASH%20White%20Paper-WPCDS008.pdf [Accessed: 10 December, 2019];
[6]
US Food and Drug Administration-Center for Drug Evaluation and Research Guidance for industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment., 2019. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry [Accessed: 10 December, 2019];
[7]
Ghobadi, C.; Johnson, T.N.; Aarabi, M.; Almond, L.M.; Allabi, A.C.; Rowland-Yeo, K.; Jamei, M.; Rostami-Hodjegan, A. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin. Pharmacokinet., 2011, 50(12), 809-822.
[http://dx.doi.org/10.2165/11594420-000000000-00000 ] [PMID: 22087867]
[8]
Jones, H.; Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol., 2013, 2(8)e63
[http://dx.doi.org/10.1038/psp.2013.41 ] [PMID: 23945604]
[9]
Marsousi, N.; Desmeules, J.A.; Rudaz, S.; Daali, Y. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J. Pharm. Sci., 2017, 106(9), 2380-2391.
[http://dx.doi.org/10.1016/j.xphs.2017.04.035 ] [PMID: 28456730]
[10]
Howgate, E.M.; Rowland Yeo, K.; Proctor, N.J.; Tucker, G.T.; Rostami-Hodjegan, A. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica, 2006, 36(6), 473-497.
[http://dx.doi.org/10.1080/00498250600683197 ] [PMID: 16769646]
[11]
Johnson, T.N.; Tucker, G.T.; Tanner, M.S.; Rostami-Hodjegan, A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl., 2005, 11(12), 1481-1493.
[http://dx.doi.org/10.1002/lt.20519 ] [PMID: 16315293]
[12]
Wilson, Z.E.; Rostami-Hodjegan, A.; Burn, J.L.; Tooley, A.; Boyle, J.; Ellis, S.W.; Tucker, G.T. Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br. J. Clin. Pharmacol., 2003, 56(4), 433-440.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01881.x ] [PMID: 12968989]
[13]
Zhang, H.; Gao, N.; Tian, X.; Liu, T.; Fang, Y.; Zhou, J.; Wen, Q.; Xu, B.; Qi, B.; Gao, J.; Li, H.; Jia, L.; Qiao, H. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci. Rep., 2015, 5, 17671.
[http://dx.doi.org/10.1038/srep17671 ] [PMID: 26635233]
[14]
Mahmoud, M.; Abdel-Kader, R.; Hassanein, M.; Saleh, S.; Botros, S. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. Eur. J. Pharmacol., 2007, 569(3), 222-227.
[http://dx.doi.org/10.1016/j.ejphar.2007.04.061 ] [PMID: 17628532]
[15]
Hallifax, D.; Foster, J.A.; Houston, J.B. Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm. Res., 2010, 27(10), 2150-2161.
[http://dx.doi.org/10.1007/s11095-010-0218-3 ] [PMID: 20661765]
[16]
Branch, R.A.; Shand, D.G. Propranolol disposition in chronic liver disease: a physiological approach. Clin. Pharmacokinet., 1976, 1(4), 264-279.
[http://dx.doi.org/10.2165/00003088-197601040-00002 ] [PMID: 797499]
[17]
Soberman, R.; Brodie, B.B.; Levy, B.B.; Axelrod, J.; Hollander, V.; Steele, J.M. The use of antipyrine in the measurement of total body water in man. J. Biol. Chem., 1949, 179(1), 31-42.
[PMID: 18119217]
[18]
Vesell, E.S.; Passananti, G.T.; Glenwright, P.A.; Dvorchik, B.H. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin. Pharmacol. Ther., 1975, 18(3), 259-272.
[http://dx.doi.org/10.1002/cpt1975183259 ] [PMID: 1164816]
[19]
Boobis, A.R.; Brodie, M.J.; Kahn, G.C.; Toverud, E-L.; Blair, I.A.; Murray, S.; Davies, D.S. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br. J. Clin. Pharmacol., 1981, 12(6), 771-777.
[http://dx.doi.org/10.1111/j.1365-2125.1981.tb01305.x ] [PMID: 7340879]
[20]
McLeay, S.C.; Morrish, G.A.; Kirkpatrick, C.M.; Green, B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin. Pharmacokinet., 2012, 51(5), 319-330.
[http://dx.doi.org/10.2165/11598930-000000000-00000 ] [PMID: 22439649]
[21]
Riede, U.N.; Spycher, M.A.; Gitzelmann, R. Glycogenosis type I (glucose 6-phosphatase deficiency): I. Ultrastructural morphometric analysis of juvenile liver cells. Pathol. Res. Pract., 1980, 167(1), 136-150.
[http://dx.doi.org/10.1016/S0344-0338(80)80185-3 ] [PMID: 6935637]
[22]
Rohr, H.P. L黷hy, J.; Gudat, F.; Oberholzer, M.; Gysin, C.; Bianchi, L. Stereology of liver biopsies from healthy volunteers. Virchows Arch. A Pathol. Anat. Histol., 1976, 371(3), 251-263.
[http://dx.doi.org/10.1007/BF00433072 ] [PMID: 823698]
[23]
Marceau, P.; Biron, S.; Hould, F-S.; Marceau, S.; Simard, S.; Thung, S.N.; Kral, J.G. Liver pathology and the metabolic syndrome X in severe obesity. J. Clin. Endocrinol. Metab., 1999, 84(5), 1513-1517.
[http://dx.doi.org/10.1210/jcem.84.5.5661 ] [PMID: 10323371]
[24]
Merrell, M.D.; Cherrington, N.J. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab. Rev., 2011, 43(3), 317-334.
[http://dx.doi.org/10.3109/03602532.2011.577781 ] [PMID: 21612324]
[25]
Idilman, I.S.; Keskin, O.; Celik, A.; Savas, B.; Elhan, A.H.; Idilman, R.; Karcaaltincaba, M. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol., 2016, 57(3), 271-278.
[http://dx.doi.org/10.1177/0284185115580488 ] [PMID: 25855666]
[26]
Noureddin, M.; Lam, J.; Peterson, M.R.; Middleton, M.; Hamilton, G.; Le, T.A.; Bettencourt, R.; Changchien, C.; Brenner, D.A.; Sirlin, C.; Loomba, R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology, 2013, 58(6), 1930-1940.
[http://dx.doi.org/10.1002/hep.26455 ] [PMID: 23696515]
[27]
Szczepaniak, L.S.; Nurenberg, P.; Leonard, D.; Browning, J.D.; Reingold, J.S.; Grundy, S.; Hobbs, H.H.; Dobbins, R.L. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab., 2005, 288(2), E462-E468.
[http://dx.doi.org/10.1152/ajpendo.00064.2004 ] [PMID: 15339742]
[28]
Nawaratne, S.; Brien, J.E.; Seeman, E.; Fabiny, R.; Zalcberg, J.; Cosolo, W.; Angus, P.; Morgan, D.J. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br. J. Clin. Pharmacol., 1998, 46(5), 447-452.
[http://dx.doi.org/10.1046/j.1365-2125.1998.00812.x ] [PMID: 9833597]
[29]
Luoma, P.V.; Sotaniemi, E.A. Saliva and plasma clearance of antipyrine as reflectors of liver function. Eur. J. Drug Metab. Pharmacokinet., 1981, 6(4), 261-264.
[http://dx.doi.org/10.1007/BF03189523 ] [PMID: 7333326]
[30]
Meffin, P.J.; Williams, R.L.; Blaschke, T.F.; Rowland, M. Application of salivary concentration data to pharmacokinetic studies with antipyrine. J. Pharm. Sci., 1977, 66(1), 135-137.
[http://dx.doi.org/10.1002/jps.2600660140 ] [PMID: 833730]
[31]
Danhof, M.; van Zuilen, A.; Boeijinga, J.K.; Breimer, D.D. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur. J. Clin. Pharmacol., 1982, 21(5), 433-441.
[http://dx.doi.org/10.1007/BF00542332 ] [PMID: 7075648]
[32]
Sinha, J.; Duffull, S.B.; Green, B.; Ponnuswamy, T.; Devanand, B.; Ramanathan, M.; Ramalingam, S.; Al-Sallami, H.S. Abstracts for the Ninth American Conference on Pharmacometrics. (ACoP9): Abstract No. T-014. J. Pharmacokinet. Pharmacodyn., 2018, 45(1), 3-134.
[PMID: 28884259]
[33]
Sinha, J.; Duffull, S.B.; Green, B.; Al-Sallami, H.S. Evaluating the relationship between lean liver volume and fat-free mass. Clin. Pharmacokinet., 2019, 59, 475-483.
[http://dx.doi.org/10.1007/s40262-019-00824-7]
[34]
Tunblad, K.; Lindbom, L.; McFadyen, L.; Jonsson, E.N.; Marshall, S.; Karlsson, M.O. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J. Pharmacokinet. Pharmacodyn., 2008, 35(5), 503-526.
[http://dx.doi.org/10.1007/s10928-008-9099-z ] [PMID: 19011957]
[35]
Dowell, J.A.; Knebel, W.; Ludden, T.; Stogniew, M.; Krause, D.; Henkel, T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol., 2004, 44(6), 590-598.
[http://dx.doi.org/10.1177/0091270004265644 ] [PMID: 15145966]
[36]
Begg, E.J.; Chin, P.K. A unified pharmacokinetic approach to individualized drug dosing. Br. J. Clin. Pharmacol., 2012, 73(3), 335-339.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04089.x ] [PMID: 21851378]

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy